利格列汀对高心血管和肾脏风险2型糖尿病患者主要心血管事件的影响:CARMELINA随机临床试验
CARMELINA试验纳入6991例高心血管和肾脏风险的2型糖尿病患者,随机接受利格列汀5mg每日一次或安慰剂。
要点
- 利格列汀对高心血管和肾脏风险的2型糖尿病患者主要心血管复合终点非劣于安慰剂。
- 两组不良事件、低血糖和急性胰腺炎发生率相似。
核心结论
- 在高心血管和肾脏风险的2型糖尿病成人中,利格列汀加常规治疗相比安慰剂加常规治疗,中位2.2年随访期内主要心血管复合终点风险非劣。
研究设计与样本
- 随机、安慰剂对照、多中心非劣效性试验,2013年8月至2016年8月在27个国家605个临床中心进行。
- 纳入6991例2型糖尿病成人,HbA1c 6.5%-10.0%,高心血管风险(血管疾病史和UACR>200 mg/g)和高肾脏风险(eGFR降低和微量或大量白蛋白尿),排除终末期肾病患者。
- 参与者随机接受利格列汀5 mg每日一次(n=3494)或安慰剂每日一次(n=3485),加常规治疗;最终随访至2018年1月18日。
- 6979例接受至少一剂研究药物,98.7%完成研究;平均年龄65.9岁,平均eGFR 54.6 mL/min/1.73 m2,80.1% UACR>30 mg/g。
主要发现
- 中位随访2.2年,主要复合终点(心血管死亡、非致死性心肌梗死或非致死性卒中)在利格列汀组发生434/3494(12.4%),安慰剂组420/3485(12.1%)。
- 不良事件发生率利格列汀组77.2%(2697例)、安慰剂组78.1%(2723例);低血糖发生率分别为29.7%(1036例)和29.4%(1024例);裁决确认的急性胰腺炎事件分别为9例(0.3%)和5例(0.1%)。
关键数值与推荐
- 非劣效性标准:利格列汀相对安慰剂的风险比(HR)双侧95%CI上限小于1.3。
临床怎么用
- 对于高心血管和肾脏风险的2型糖尿病患者,利格列汀可作为不增加主要心血管事件风险的降糖选择。
- 使用利格列汀时仍需关注低血糖和急性胰腺炎等不良事件,尽管发生率与安慰剂相似。
局限性
- 研究排除了终末期肾病患者,结果不适用于该人群。
- 中位随访时间2.2年,长期心血管和肾脏结局需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV outcomes and kidney outcomes in patients with type 2 diabetes at high risk of CV and kidney events. DESIGN, SETTING, AND PARTICIPANTS: Randomized, placebo-controlled, multicenter noninferiority trial conducted from August 2013 to August 2016 at 605 clinic sites in 27 countries among adults with type 2 diabetes, hemoglobin A1c of 6.5% to 10.0%, high CV risk (history of vascular disease and urine-albumin creatinine ratio [UACR] >200 mg/g), and high renal risk (reduced eGFR and micro- or macroalbuminuria). Participants with end-stage renal disease (ESRD) were excluded. Final follow-up occurred on January 18, 2018. INTERVENTIONS: Patients were randomized to receive linagliptin, 5 mg once daily (n = 3494), or placebo once daily (n = 3485) added to usual care. Other glucose-lowering medications or insulin could be added based on clinical need and local clinical guidelines. MAIN OUTCOMES AND MEASURES: Primary outcome was time to first occurrence of the composite of CV death, nonfatal myocardial infarction, or nonfatal stroke. Criteria for noninferiority of linagliptin vs placebo was defined by the upper limit of the 2-sided 95% CI for the hazard ratio (HR) of linagliptin relative to placebo being less than 1.3. Secondary outcome was time to first occurrence of adjudicated death due to renal failure, ESRD, or sustained 40% or higher decrease in eGFR from baseline. RESULTS: Of 6991 enrollees, 6979 (mean age, 65.9 years; eGFR, 54.6 mL/min/1.73 m2; 80.1% with UACR >30 mg/g) received at least 1 dose of study medication and 98.7% completed the study. During a median follow-up of 2.2 years, the primary outcome occurred in 434 of 3494 (12.4%) and 420 of 3485 (12.1%) in the linagliptin and placebo groups, respectively, (absolute incidence rate difference, 0.13 [95% CI, -0.63 to 0.90] per 100 person-years) (HR, 1.02; 95% CI, 0.89-1.17; P < .001 for noninferiority). The kidney outcome occurred in 327 of 3494 (9.4%) and 306 of 3485 (8.8%), respectively (absolute incidence rate difference, 0.22 [95% CI, -0.52 to 0.97] per 100 person-years) (HR, 1.04; 95% CI, 0.89-1.22; P = .62). Adverse events occurred in 2697 (77.2%) and 2723 (78.1%) patients in the linagliptin and placebo groups; 1036 (29.7%) and 1024 (29.4%) had 1 or more episodes of hypoglycemia; and there were 9 (0.3%) vs 5 (0.1%) events of adjudication-confirmed acute pancreatitis. CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01897532.
引用
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019. PMID: 30418475. doi:10.1001/jama.2018.18269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。